068330 — Ilshinbiobase Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapContrarian

Annual income statement for Ilshinbiobase Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	ARS/A	ARS	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	21,035	24,379	20,433	16,437	10,818
Cost of Revenue
Gross Profit	10,371	12,657	10,510	9,428	6,278
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	16,013	17,042	16,015	10,223	8,556
Operating Profit	5,023	7,337	4,418	6,214	2,262
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	5,365	7,816	4,704	7,755	4,628
Provision for Income Taxes
Net Income After Taxes	3,971	5,858	3,815	6,232	3,812
Minority Interest
Net Income Before Extraordinary Items
Net Income	4,479	5,858	3,815	6,232	3,812
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	4,479	5,858	3,815	6,232	3,812
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	115	137	103	148	91.5
Dividends per Share